B-Cell Therapies in Multiple Sclerosis

B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of effector functions. All currently approved MS disease-modifying therapies alter the frequency, phenotype, or homing of B cells in one way or another. The importance of this mechanism of action has been reinforc...

Full description

Saved in:
Bibliographic Details
Published in:Cold Spring Harbor perspectives in medicine 2019-02, Vol.9 (2), p.a032037
Main Authors: Sabatino, Jr, Joseph J, Zamvil, Scott S, Hauser, Stephen L
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - pharmacology
Antigens, CD20 - immunology
B-Lymphocytes - immunology
Disease Progression
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - pharmacology
Interferons - administration & dosage
Interferons - adverse effects
Interferons - pharmacokinetics
Multiple Sclerosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of effector functions. All currently approved MS disease-modifying therapies alter the frequency, phenotype, or homing of B cells in one way or another. The importance of this mechanism of action has been reinforced with the successful development and clinical testing of B-cell-depleting monoclonal antibodies that target the CD20 surface antigen. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was approved by the Food and Drug Administration (FDA) in March 2017 after pivotal trials showed dramatic reductions in inflammatory disease activity in relapsing MS as well as lessening of disability progression in primary progressive MS. These and other clinical studies place B cells at the center of the inflammatory cascade in MS and provide a launching point for development of therapies that target selective pathogenic B-cell populations.
ISSN:2157-1422
2472-5412
DOI:10.1101/cshperspect.a032037